Headline transactions ranged from Procter & Gamble’s $3.8 billion agreement to acquire Thorne and Kirin Holdings’ planned purchase of Jamieson Wellness to a steady stream of carveouts, add-on acquisitions and growth investments spanning ingredients, contract manufacturing, diagnostics and consumer health.
Several themes cut across the quarter’s announcements. Buyers sought greater control over differentiated technology, clinical evidence and supply, driving deals for fermentation capacity, branded ingredients, specialty delivery systems and CDMO capabilities. Capital also continued to flow toward personalized nutrition, microbiome intelligence, biomarker testing and preventive-health platforms—signaling that proprietary data and practitioner integration are becoming as important as formulation and brand strength.
The roundup also indicates a more global and interconnected market. Distribution agreements opened routes into Japan, Latin America and Southeast Asia; research and commercialization alliances paired ingredient developers with academic, manufacturing and consumer-facing partners; and companies used structures ranging from conventional venture rounds to financing focused on customer value to fund expansion.
Mergers & Acquisitions
Premium supplement brand Thorne, backed by L Catterton, agreed to be acquired by Procter & Gamble for $3.8 billion. Known for its science-backed formulations and health care practitioner network, Thorne generated more than $500 million in revenue last year and has established itself as a leading premium brand among younger, health-conscious consumers. The acquisition expands P&G’s existing health portfolio, which includes Metamucil, Align and New Chapter.
“This is an important step for P&G’s Personal Health Care business,” said Paul Gama, CEO of P&G Health Care. “Consumer interest in self-care, prevention, wellness and personalized health continues to grow, and Thorne strengthens our position in premium wellness with a trusted, science-backed brand that complements our existing portfolio.”
Private equity firm Yellow Wood Partners acquired Nestlé’s Holistic Health portfolio for $1 billion. The sale included brands Nature’s Bounty, Nuun, Osteo Bi-Flex, Gard, Puritan’s Pride and Sisu, along with the associated U.S. private-label supplements business, dedicated manufacturing, packaging, warehousing and distribution operations. The transaction is subject to applicable regulatory approvals and is expected to close by the first half of 2027. It marks Yellow Wood’s sixth significant carveout acquisition from five major global consumer companies, including Bayer, Reckitt, Unilever and Haleon.
“Holistic Health is an excellent platform of trusted brands with deep retailer relationships providing significant opportunities for continued growth,” said Dana Schmaltz, partner at Yellow Wood. “The Holistic Health portfolio provides a group of specialty category leaders in various high growth sectors of the attractive VMS market, including hydration, gut health and immunity.”
Nestlé will focus its resources on its premium, science-led brands Solgar and Pure Encapsulations.
L Catterton and Altas Partners agreed to acquire a majority stake in Fullscript from HGGC and Snapdragon Capital. The investment will help Fullscript further expand its platform and clinical support capabilities for practitioners and extend its reach across the North American healthcare market. Financial terms of the transaction were not disclosed.
“The convergence of conventional and functional medicine is happening at a rapid pace. Millions of Americans are seeking trusted sources of education and treatment solutions to manage chronic conditions and prevent disease in order to live their healthiest life,” said said Marc Magliacano, managing partner at L Catterton. “Practitioners require a platform that can provide trusted whole-health protocols and products that is integrated into their daily practice management and assures safety and efficacy.”
Swedish CDMO Wellma acquired Virun NutraBiosciences, strengthening its position across both the U.S. and Irish markets and expanding its international manufacturing capabilities. Founded in 2003 with operations in Los Angeles and Ireland, Virun holds over 100 patents in advanced nutrient delivery technologies including emulsion and liposomal delivery platforms for ingredients including omega-3, astaxanthin, CoQ10 and PQQ.
“What attracted me to Wellma was the opportunity to continue driving Virun with the same entrepreneurial spirit that has defined us for more than two decades, while gaining access to a broader team with deep industry expertise and growth opportunities on both sides of the Atlantic,” says Philip Bromley, founder and CEO of Virun. “Together with Wellma, we can better support our customers as they expand into Europe, while also helping Wellma’s partners strengthen their presence in the US market.”
Kirin Holdings Company agreed to acquire all of Canadian supplement manufacturer Jamieson Wellness Inc’s issued and outstanding common shares at C$45.75 per share in cash. The transaction values Jamieson Wellness at approximately C$2.0 billion on a fully diluted equity value basis and approximately C$2.5 billion (US$1.78 billion) on an enterprise value basis.
“Today marks an exciting new chapter for our company and for our iconic 104-year-old brand,” said Mike Pilato, president and CEO of Jamieson Wellness, following the announcement. “I am incredibly proud that our business will continue to flourish globally under the stewardship of a company with an even longer history and a deep commitment to health and wellness.”
Lallemand completed its acquisition of Bio-Cat Enzymes & Microbials, combining complementary expertise in enzymes, microbial technologies, fermentation and life science innovation. The terms of the transaction were not disclosed.
“The acquisition will reinforce our presence in the dietary food supplement and health ingredient markets and increase our production footprint and capacity in the USA,” said Antoine Chagnon, CEO of Lallemand. “This, in turn, should better enable us to meet the requirements of our existing and new customers across the global animal nutrition, agriculture and food industries.”
Boston-based Ayana Bio and India’s Zenfold Sustainable Technologies jointly acquired physical fermentation asset from the estate of defunct alt-protein firm Meati Foods for $75,000. The deal secures twelve 25,000-liter stainless steel fermentation tanks with, providing 300,000-liter capacity to scale plant cell culture technology.
French botanical ingredient supplier Nexira acquired Moroccan carob specialist Keragum to strengthen supply chain control and improve traceability amid increasing demand for natural, clean-label ingredients.
“Our ambition is to invest as close as possible to production, securing high-quality raw materials while generating tangible local value,” said Mathieu Dondain, VP and CEO of Nexira. “Together, Keragum and Nexira will drive the stability, sustainability and long-term growth of a market we deeply believe in.”
European CDMO Group 1Q Health, part of Nord Holding’s portfolio, acquired Swiss softgel manufacturer Gelpell AG to further strengthen the group’s footprint across the DACH region. The acquisition continues Nord Holding’s build-out of 1Q Health Group. The platform was formed through the purchases of ABJ alive and HKS health solutions, followed by add-on deals for VivaCell Biotechnology, Beauty Production and EHF Production. Gelpell offers services across the value chain, from product development and contract manufacturing to regulatory support and packaging.
Ingredient supplier SuanNutra and Carbyne Equity Partners announced plans to acquire IFF’s specialty natural ingredients business, adding branded ingredients, botanical extracts, fermented vitamins and minerals, natural colors, antioxidants and flavors. The merged group of around 700 employees will operate across Spain, Slovenia and Peru and the United States.
Anthony Weston, group CEO of SuanNutra, said the company is focused on integrating its new operations, strengthening its commercial organization and driving growth across its six product categories, with further expansion planned in the United States and Asia while continuing to grow in Europe and Latin America. It also plans to prioritize higher-value, clinically supported branded ingredients through continued investment in clinical research and product development.
Private equity firm Bain Capital purchased UK-supplement brand Vitabiotics in a deal valued at approximately £900 million. Founded in 1971 by Professor Kartar Lalvani OBE, the Vitabiotics Group has built leading positions across India, China, Egypt and the wider MENA region. Its portfolio of leading brands includes Pregnacare, Perfectil, Wellman, Wellwoman, Osteocare and the Ultra range. Bain Capital will contribute local market knowledge in India, together with sector expertise, portfolio resources and global capabilities, to support Vitabiotics as it continues to scale its brands, strengthen its international platform and invest in long-term growth within key markets such as MENA and China.
“This direction is not about changing who we are; it is about accelerating what we can become,” said Tej Lalvani, group CEO of Vitabiotics. “With Bain Capital’s global expertise and investment behind us, we have a unique opportunity to expand internationally, accelerate our innovation and take our trusted brands to millions more consumers, while staying true to the science, quality and values that have defined Vitabiotics for more than 55 years.”
cbdMD completed the acquisition of legacy supplement brand Twinlab in a deal valued at roughly $4 million, expanding into sports nutrition and longevity categories. The transaction is expected to reduce cbdMD’s revenue concentration in the hemp category and mitigate risks associated with the evolving regulatory environment for hemp-derived products. The agreement follows cbdMD’s earlier acquisition and integration of Bluebird Botanicals.
Melbourne-based Elixinol Wellness signed a binding agreement to acquire Australian personalized supplement subscription platform Vitable in an all-scrip deal worth up to $3.5 million. The structure includes $2.5 million in upfront equity, paid across five tranches in Elixinol shares, plus US$647.1K “platform kicker” tied to performance milestones.
Vitable’s service and personalized supplements are currently available across Australia, New Zealand, Singapore, the United Kingdom, Hong Kong and the Philippines, with some 7,850 active subscribers and 1.84 million customer health assessments completed through its platform. The company’s international expansion was supported by A$5.5 million in funding in 2021. Elixinol, which markets whole foods, fiber, protein and better-for-you pantry products, sold its U.S. business to Ananda Health earlier this month to focus on its core business.
“Vitable brings Elixinol an established subscription-based consumer platform, proprietary personalization capability and direct consumer relationships,” said Natalie Butler, CEO and executive director at Elixinol. “These capabilities are highly complementary to our existing Australian health and wellness brands and create clear opportunities to grow customer value across the Group.”
Solabia Group completed the acquisition of ingredient company Mibelle Biohemistry from Spanish family-owned multinational company Persán under terms first announced in February. Founded in Switzerland in 1991, Mibelle is known worldwide for its work in plant stem cell technology and modern biotechnology, with a portfolio covering skin beauty, healthy aging, hair care and cognitive support. Its actives are distributed in more than 50 countries.
Novonesis signed an agreement with the intent to acquire Australian biotechnology company MicroBioGen to strengthen its yeast capabilities for bioethanol production. The acquisition builds on Novonesis’ 2013 investment in MicroBioGen and its current 23% stake. The terms of the deal were not disclosed, and completion of the transaction is subject to customary regulatory approvals, including by the ACCC, Australia’s national competition, consumer, fair trading and product safety regulator.
“This acquisition marks an additional step in our 2030 strategy,” said Ester Baiget, CEO at Novonesis. “It strengthens our yeast capabilities, strengthens our R&D capabilities, and reflects our disciplined investment focus to drive growth.”
Key takeaways
• Premium wellness is an attractive target: Buyers continue to prioritize scaled supplement brands with strong consumer trust, scientific positioning and established routes to market.
• Portfolio reshaping is accelerating: Large companies are divesting noncore assets and concentrating resources on premium, differentiated and science-led businesses.
• Private equity remains a major force in consolidation: Private equity firms are using carveouts, platform investments and add-on acquisitions to build broader health, wellness and manufacturing portfolios.
• Manufacturing scale and technical specialization are in demand: Acquirers are seeking expanded capacity and expertise in delivery technologies, fermentation, enzymes, microbials, softgels and other specialized formats.
• Vertical integration is strengthening supply resilience: Ingredient-focused transactions reflect growing interest in traceability, raw-material access, quality control and greater oversight of production.
• Digital and personalized health are moving into the mainstream: Practitioner integration, subscription models, proprietary data and direct consumer relationships are becoming increasingly valuable deal assets.
• Cross-border expansion remains a recurring objective: Acquisitions are being used to enter new markets, broaden distribution and combine global reach with local manufacturing and regulatory expertise.
Strategic partnerships & alliances
Asahi Group Foods entered into a sales agreement with Maypro Industries for the international sale of its proprietary milk peptide Lactononadecapeptide (LNDP) from July 2026 onward. Maypro, founded in 1977 by Japanese entrepreneur Steve Yamada in New York, is expected to progressively roll out the product across global markets, primarily in North America, for use in supplements and health foods.
This marks the Asahi Group Foods’ first-time selling LNDP outside the Asahi group and to international markets. A milk peptide consisting of 19 amino acids, which was discovered in milk fermented with lactic acid bacteria, the ingredient has been reported to help maintain attention and cognitive functions that support efficiency of calculation tasks, and it is used as an ingredient in supplements and beverages sold by the Asahi Group in Japan.
Spanish ingredient supplier Bioiberica partnered with Ryusendo Co. to distribute its Collavant n2 native (undenatured) type II collagen joint-health ingredient to the Japanese market. The distribution partnership marks Bioiberica’s first entry into the Japanese nutraceutical space and a joint-health market fueled by an aging population and a growing interest in preventative mobility support.
“Our established reputation for circular, fully traceable production has also played an important role in bringing Collavant n2 to Japan,” said Antonio Vendrell, marketing & communications director at Bioiberica. “Meeting the country’s stringent import and quality regulations requires complete transparency across the supply chain, an area where our processes are well-placed to deliver. Looking ahead, we see this agreement as the key that unlocks limitless opportunities in one of the world’s most dynamic and innovative nutraceutical markets.”
Norwegian marine ingredient company Calanus AS entered into an exclusive partnership with Okura Chem-Tech Corp., appointing the Osaka-based company as its exclusive importer, distributor and commercial partner for Zooca Calanus Oil in Japan.
“Japan is at the forefront of healthy aging, product quality and nutritional innovation,” said Ole Sakkestad, chief sales officer for human health & nutrition at Zooca. “Zooca Calanus Oil combines a distinctive marine lipid composition with strong sustainability credentials and scientific documentation. Together with Okura Chem-Tech Corp., we look forward to building a strong, long-term position in Japan.”
The U.S.-based Organic & Natural Health Association and the Shellac & Forest Products Export Promotion Council (SHEFEXIL), an export promotion council sponsored by India’s Ministry of Commerce & Industry, entered into a strategic partnership to strengthen scientific collaboration, trusted supply chains and responsible trade between the United States and India for natural health products, nutraceuticals, botanicals and functional ingredients. Planned activities include executive exchanges, regulatory roundtables, scientific forums, trade missions, buyer and seller introductions, educational programming, manufacturing and research facility visits, academic exchanges and working groups addressing emerging issues affecting the global natural health industry.
“Our partnership with the Organic & Natural Health Association creates a stronger bridge between India and the United States for science, innovation, and responsible commerce,” said Debjani Roy, Ph.D., executive director of SHEFEXIL. “Together, we are building a trusted global ecosystem through scientific collaboration, regulatory dialogue, and industry engagement that benefits both consumers and the natural health sector.”
GNC and DFI Retail Group announced a strategic partnership to deepen access to GNC’s health and wellness solutions in Singapore. This builds on a successful two-decade long collaboration between the two in Hong Kong, one of GNC’s largest markets in Asia, strengthening GNC’s presence in Singapore through a multi-year channel retail model. Under this expanded partnership, DFI will now also serve as GNC’s exclusive wholesaler, distributor and franchisee in Hong Kong, Macau and Singapore. Products will be available in-store and online through Guardian beginning Q4 2026, as well as exclusively at GNC’s standalone stores, with locations to be announced at a later stage. The partnerships comes after the May 2026 Singapore Court of Appeal decision to uphold and enforce GNC’s rights to assume former GNC store leases in full.
“For more than three decades, Singapore consumers have placed their trust in the GNC brand,” said Cheri Mullen, chief global franchise and wholesale officer at GNC. “We are proud to expand our successful partnership with DFI Retail Group beyond Hong Kong into Singapore. We look forward to reconstituting our store footprint in Singapore and remain focused on rebuilding and strengthening our presence in the market while continuing to deliver the quality, innovation and science-backed wellness solutions consumers expect from GNC.”
Novonesis entered an agreement with precision fermentation company TurtleTree for the scaling, manufacturing and commercialization of its lactoferrin LF+ ingredient. Under the agreement, Novonesis will exclusively undertake efforts to scale, manufacture and commercialize LF+ for the early life nutrition market and will have selected commercial rights for dietary supplements. Novonesis is simultaneously making a minor investment into TurtleTree, along with 321Catalyst Ventures, the CVC-arm of Mitsui Chemicals, Inc.
“Our aim is to make lactoferrin more accessible and cost-competitive and showcase what is achievable with precision fermentation in early life nutrition and dietary supplements,” said Thomas Batchelor, senior vice president for early life and specialized nutrition at Novonesis. “If successfully scaled, this will enable customers to deliver proven health benefits to consumers more efficiently. LF+®fits well in our broader portfolio of both precision fermentation projects and our specialized nutrition ingredients.”
South Korean biohealth firm NVP Healthcare signed an exclusive supply agreement with Brazilian pharmaceutical major Marjan Farma, establishing a regional hub in Brazil to commercialize its proprietary NVP-1702 probiotic ingredient across Latin America. Under the agreement, NVP Health care will offer regulatory and technical support, while Marjan Farma will develop and commercialize finished products for the local market.
Wellness brand Cymbiotika partnered with personalized health and biomarker testing platform Hundred Health to offer qualifying Cymbiotika supplement subscriptions an integrated, data-driven wellness program that combines comprehensive at-home biomarker testing, medical history and wearable data to give Cymbiotika customers a personalized 100-day plan for their health.
“For too long, wellness has meant giving everyone the same protocol and hoping it works,” said Chervin Jafarieh, co-founder and chief scientific officer of Cymbiotika. “That era is over. Cymbiotika has always believed in real intention and real science behind every formula — and this partnership is how we take that from generalized wellness to truly individualized wellness.”
Austin-based cardiovascular health supplement company Humann established an open-ended research partnership with the UC Davis Innovation Institute for Food and Health to develop intellectual property in precision cardiovascular and metabolic health. The partnership seeks to investigate how precision nutrition approaches can improve cardiovascular health, performance and longevity to build a stronger scientific foundation for future innovation in the food and dietary supplements categories.
“Humann started with the belief that nutrition can play a meaningful role in supporting cardiovascular health, but we’ve always known there is much more to discover,” said Joel Kocher, CEO and cofounder of Humann. “Scientific partnerships have always been central to how we build this company, and our collaboration with IIFH gives us the opportunity to deepen our understanding of how nutrition can support cardiovascular health.”
Bevimi, a company focused on brain health and cognitive longevity, has entered an official partnership with RESOLV Proving Ground, a nonprofit dedicated to the physical and mental health of Special Operations Veterans. The partnership will combine RESOLV’s physical and neuro training methods with Bevimi’s targeted cognitive supplements to support mental resilience and leverage mutual insights to raise the bar for veteran care and healthspan.
The New York Jets and VitaCholine announced their continued collaboration to help fans understand the role of choline in supporting brain and body health, through game-day education and interactive experiences at MetLife Stadium.
“Choline supports both brain and body health, yet many consumers still do not recognize its role,” said Dr. Eric Ciappio, senior manager of nutrition science at Balchem. “By pairing the Jets’ game-day reach with nutrition education, we can help fans understand why this essential nutrient matters and provide practical, science-based information they can use to make more informed nutrition choices for everyday performance and wellness.”
USANA Health Sciences renewed its official partnership with Nordiq Canada, the national governing body for cross-country skiing in Canada. Under the renewed agreement, USANA will continue supplying Nordiq Canada’s elite athletes with premium, NSF Certified for Sport nutritional products designed to support performance, normal muscle recovery after exercise and long-term health through the 2030 Olympic Winter Games and beyond.
“Canada has a passionate and knowledgeable fan base for cross-country skiing, and Nordiq Canada’s athletes inspire millions of Canadians every time they compete,” said Tracie Kenzora, general manager of Canada at USANA. “This renewal is a reflection of USANA’s deep commitment to the Canadian market and to the athletes and communities we serve here. We’re thrilled to continue standing behind some of the country’s finest athletes as they chase their dreams on the world stage.”
Wellness platform and community TRU47 announced a strategic partnership with USA Pickleball. The partnership will introduce TRU47—which initially focused on medicinal silver and grounding products but has since expanded to offer supplements—to USA Pickleball’s nationwide community through digital marketing, player education, product sampling, ambassador and influencer campaigns, live-event activations, original content and e-commerce initiatives. USA Pickleball surpassed 130,000 members in 2025 and is supported by more than 1,800 ambassadors nationwide.
“Our partnership with USA Pickleball is about much more than sponsorship,” said Edward Bugniazet, CEO of Rye Strategic Partners and Chairman of TRU47. “Pickleball is a demanding, fast-growing sport, and its players represent the exact active, health-conscious community our products are designed for. We’re building a curated wellness platform and community that directly supports these everyday athletes’ performance and recovery needs through education, authentic content and trusted, innovative tools.”
Key takeaways
• International market access is a central partnership objective: Suppliers and brands are working with local distributors, importers and retailers to navigate new markets and accelerate commercialization.
• Local expertise is becoming critical to expansion: Regional partners provide regulatory knowledge, established channels and market-specific capabilities that can reduce barriers to entry.
• Science and commercialization are increasingly intertwined: Alliances are pairing research, technical validation and intellectual-property development with manufacturing scale and market execution.
• Personalization is driving new ecosystem partnerships: Biomarker testing, wearable data and tailored protocols are being integrated with supplement offerings to create more individualized wellness programs.
• Sports and community platforms as education channels: Brands continue to use athlete, fan and active-lifestyle partnerships to build awareness through education, events and digital engagement.
• Partnerships are broadening beyond conventional distribution: Agreements increasingly combine research, manufacturing, education, marketing, product development and long-term commercial rights.
Investments & stakes
Tiny Health closed $33 million in Series B funding, led by B Capital, bringing the gut and vaginal microbiome intelligence platform’s total funding to $46 million. New investors include Black Opal Ventures, Denver Ventures, Pave Health Ventures, Alumni Ventures, Gaingels and Pari Passu Ventures, alongside continued support from Spero Ventures, TheVentureCity, Overwater Ventures and others. The gut and vaginal microbiome intelligence platform will use the capital to advance clinical research and interventional studies, expand its healthcare practitioner education, scale its Powered by Tiny platform and accelerate TinyAI, an AI trained on Tiny Health’s proprietary dataset of nearly 200,000 microbiome profiles to deliver personalized, science-backed guidance tied directly to a user’s results. In tandem with the raise, Tiny Health announced the launch of a $5 million Microbiome Research Program to accelerate microbiome research.
India-based ingredient supplier Nutriventia announced that it had closed a strategic growth investment from NDude Labs, a healthcare/wellness investment holding company with operations in India and the United States. The capital is earmarked for clinical R&D, expansion of proprietary branded ingredients, scaling its delivery platform, establishing dedicated U.S. commercial operations and subsequent expansion into Europe and APAC.
“We built our proprietary delivery platforms to solve genuine pharmaceutical-grade challenges around bioavailability, stability and efficacy,” said Vishal Shah, co-founder and managing director at Nutriventia. “This partnership ensures that we can deepen our clinical pipeline and advance our delivery platforms without compromising scientific rigor.”
Utah-based CDMO WB Blends, backed by private equity firm The Riverside Company, acquired a majority stake Oregon-based consumer products company Yellow Emperor, expanding its capabilities beyond capsules and powders into tinctures, extracts and liquid herbal supplements. Yellow Emperor, founded in 1981, will continue to operate under its current name, day-to-day operations will remain unchanged, and products will continue to be manufactured in the same facilities.
“Consumers keep gravitating toward vitamin, mineral and supplement (VMS) products and natural wellness solutions, creating attractive long-term growth for CDMOs with specialized capabilities,” said Brad Roberts, co-chief investment officer of Riverside’s Capital Appreciation strategy. “Yellow Emperor is a natural complement to Western Botanicals, deepening its liquid platform, strengthening R&D, and opening new ways to serve customers.”
David Beckham-backed wellness brand IM8 secured a novel $1 billion growth-financing structure from General Catalyst. Under the arrangement, General Catalyst’s Customer Value Fund finances up to 70% of IM8’s marketing spend, with IM8 retaining full discretion over facility utilization. In return, General Catalyst receives capped share of income that is tied to the performance of customer cohorts financed through the program, capped at predetermined levels. Once General Catalyst has recovered its investment and capped return on any given monthly cohort, all subsequent value from those customers accrues entirely and permanently to IM8. The arrangement does not involve the issuance of any equity, warrants or convertible instruments to General Catalyst, and is tracked separately for each monthly cohort of customers.
“Nineteen months ago, IM8 was an idea David Beckham and I were building around one belief: that people deserve premium science-backed products they can trust every day,” Danny Yeung, CEO and co-founder of parent company Prenetics, shared in a press July 14 press release. “Today it’s the fastest-growing premium supplement brand ever recorded, and General Catalyst’s $1 billion commitment validates the strength of the cohort economics we’ve built. Every mature customer cohort since launch has exceeded the performance thresholds General Catalyst diligenced against, cohort after cohort, in the deepest diligence process I’ve been through as a founder.”
With the financing, IM8 plans to accelerate brand and marketing across its 43 countries without issuing a single share to fund it as it continues to build a multi-billion-dollar global consumer health brand.
Novonesis announced plans to invest ₹6,660 crore (over $694 million) in Maharashtra over the next 24 to 36 months, with a significant portion expected to go towards developing unused land to expand its manufacturing facility in the industrial district of Patalganga to meet the growing domestic demand for biofuels, agricultural biologicals and health solutions. The expanded facility is scheduled to be fully operational by 2030. In addition to Patalganga, Novonesis operates a facility in Wada, Maharashtra, producing enzymes, health ingredients, and nutrition products for both domestic and export markets. The investment aligns with the company’s broader strategy focusing on customers in emerging markets across the Middle East, India and Africa.
Unilever announced plans to develop a new global innovation center in New Haven, Conn., opening by spring 2029. The multinational consumer goods company says that the $270-million investment reflects its belief in science-led growth and the increasingly central role of the United States in driving innovation across its business. The long-term investment includes $50 million in capital expenditure—the company’s largest in the United States in 40 years—and builds on $15 billion invested in its U.S. business over the past decade, across both acquisitions and capital projects.
“This new center is where we’ll innovate at the intersection of science, technology and culture,” Herrish Patel, president of Unilever USA and CEO of Personal Care North America, shared in a release. “As the US becomes a center of gravity for Unilever, we’re harnessing the best of American innovation to match our growth ambition here in the US and around the world.”
India-based nutrition brand Supply6 raised $5.7 million Series A led by Unilever Ventures, targeting $83 million in revenue by 2030, with participation from Zeropearl VC and actress Kriti Sanon. The funding will support the Supply6’s next phase of growth across product innovation, clinical research, supply chain, digital experience, and expansion across direct-to-consumer, marketplaces and quick commerce channels. The company’s flagship product, Supply6 360, is an all-in-one foundational nutrition supplement that combines 63+ ingredients, including probiotics, essential micronutrients and adaptogens.
Throne Science closed a $10 million $10 million Series A funding round led by Will Ventures, with participation from Emerson Collective, Workshop, LEAD VC, Salt VC, Accomplice, Moxxie, Ventures Together, Symphony, Felix Capital, Cosmic Venture Partners, Offscript, V1.VC, and Morrison Seger. Founded in 2023, the company created a sensor that attaches to any standard toilet and uses computer vision to track gut health, hydration and urinary function. With the new funds, Throne will seek to expand its team and advance R&D efforts for the next generation of the device, which the founders aim to transition into an early detector for colon cancer and other potentially life-threatening conditions.
“Throne is building a platform that will not only provide valuable data about gut health and hydration, but in future iterations of the technology, will also sound alarms regarding more serious health conditions,” said Throne CEO and founder Scott Hickle. “This raise is an important stepping stone to build the infrastructure we need to get to the next level.”
Plantible, a startup extracting protein from duckweed, raised $35 million to expand operations at its site in Eldorado, TX. The financing package, split into a $25 million USDA-backed loan from X-Caliber Rural Capital and a $10 million equity investment from RA Capital and existing investors, will enable Plantible to increase annual production capacity for its duckweed-derived “Rubi protein” five-fold to over 1,000 metric tons.
Function Health received $450 million in growth financing from General Catalyst’s Customer Value Fund to scale its tech-enabled preventive health, lab testing and imaging platform. The round comes eight months after Function’s $298 million Series B, backed by investors including Matt Damon and Zac Efron, and the company’s acquisition of Getlabs in April for at home blood draws and supplement rating, tracking and verification platform SuppCo.
Fertility testing and supplement platform Bird&Be raised $13M to fund product development, clinical research and expansion across retail and healthcare providers. The round was led by BDC Thrive and BFG Partners, with the participation of BAM Ventures and Founder Collective. Launched in 2021, the brand crossed $10m in revenue within three years and is growing nearly 100% year-on-year with DTC driving 85% of sales.
Women’s health precision startup Evvy raised a $40 million series B, in an oversubscribed round led by Catalio Capital Management and bringing the company’s total equity raised to nearly $60 million. Since its founding in 2021, Evvy has built the world’s largest proprietary, clinical-grade dataset on the vaginal microbiome and women’s health outcomes — and the machine learning engine, Evvy AI, that interprets large-scale biological data to transform patient care. This round will fund the validation of a new generation of AI-driven diagnostic and care models across women’s health, starting with fertility.
“We were drawn to Evvy not only because of its growth, but because of the unique data and AI infrastructure the company is building, and the exceptional team executing on it,” said Jacob Vogelstein, cofounder and managing partner at Catalio Capital Management. “Its combination of proprietary data, clinical evidence and a growing biomarker discovery engine creates an entirely new foundation for precision women’s healthcare. We believe Evvy is building the data platform that will define this category for decades to come.”
Other investors in the latest round included Rethink Impact, Muse Capital and Alumni Ventures, alongside existing investors LabCorp Venture Fund, General Catalyst, Left Lane Capital, BBG Ventures, Amboy Street Ventures, Ingeborg, Foreground Capital and Flywheel Ventures.
London-based functional wellness brand Reformed closed an oversubscribed $22 million Series A round led by IRIS Ventures. Founded in 2024, Reformed sells coffee, matcha and mocha blends with added ingredients such as collagen, creatine, vitamins or minerals and reports achieving a $70 million annualized revenue run rate and profitability just two years launch. JamJar Investments, V3 Ventures and FoodLabs also participated in the funding round.
Italian functional foodtech startup Nous secured a €2.3 million seed funding round commercialize Koncentra, its caffeine-free botanical ingredient designed to promote natural energy, focus and mood. The round was led by dsm-firmenich Ventures alongside FoodSeed and Eatable Adventures. The company also plans to use the funding to run further clinical trials, expand supply chains in Europe and Asia, grow its team and develop additional functional ingredients. It is targeting a U.S. market entry by the end of 2026.
Canadian wellness company Organic Traditions raised $10.5 million in Series A financing to accelerate U.S. expansion, expand retail distribution, push innovation behind its Fiber Flow line and invest in the team and infrastructure it needs for continued North American growth. It expects to add products to more than 1,500 US retail doors in 2026, building on a Canadian retail network that already includes over 6,000 stores. The round drew strategic angel investors with backgrounds in consumer packaged goods, retail, technology, and operations, including executives and operators from FreshPet, Shopify, City National Bank, Frito-Lay, and Colgate-Palmolive.
Cymbiotika, best known liposomal supplement squeeze packs, brought on fashion and beauty influencer Alix Earle as investor. As part of the partnership, Earle will use her platform of 14 million followers across YouTube, TikTok and Instagram to promote the brand. The company, which was bootstrapped until January of this year when it brought in $25 million in outside capital, with backers including Kendall Jenner, Hailey Bieber, David Grutman, Zac Efron, The Weeknd, Steve Aoki, Peggy Gou, and the Jonas Brothers. The company reported $150 million in annual revenue in 2025.
North American contract research organization KGK Science Inc. secured a growth investment led by Maxim Partners, a Chicago-based firm that partners with education and wellness founders and managers. The growth investment will support expanded clinical trial capacity, continued development of virtual trial technology and expansion of KGK’s regulatory services. Financial terms were not disclosed.
“I founded KGK to address a growing and underserved need to bring scientific rigor to the marketing of nutritional supplements,” said Najla Guthrie, founder and CEO of KGK Science. “This partnership with Maxim is a powerful endorsement of what our team has built and of the growing role that credible science plays in this market.”
Key takeaways
• Precision and preventive health are attracting substantial capital: Investors are backing platforms that combine diagnostics, biomarker testing, microbiome insights and personalized guidance to support earlier and more individualized intervention.
• Proprietary data and AI are emerging as core assets: Funding is increasingly directed toward businesses that can turn large, specialized health datasets into research tools, clinical insights and scalable consumer services.
• Clinical validation remains central to growth strategies: Companies are allocating new capital to trials, research infrastructure, practitioner education and regulatory capabilities as evidence becomes more important to differentiation.
• Manufacturing capacity and specialized formats are investment priorities: Capital is supporting facility expansion, production scale and broader capabilities across ingredients, liquids, extracts and other value-added delivery systems.
• Global and omnichannel expansion is a recurring use of proceeds: Brands are investing in new geographic markets, retail distribution, direct-to-consumer platforms, marketplaces and faster-commerce channels to broaden reach.
• Functional wellness continues to diversify: Investment spans women’s health, gut health, foundational nutrition, functional beverages, novel proteins and next-generation ingredients, reflecting demand for more targeted solutions.
